Does nonmetastatic castration-resistant prostate cancer still exist?

被引：0
|
作者：
Celestia S. Higano
机构：
[1] University of Washington,Division of Medical Oncology, Department of Medicine
[2] Fred Hutchinson Cancer Research Center,undefined
[3] Seattle Cancer Care Alliance,undefined
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
After almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered.
引用
收藏
页码：350 / 351
页数：1
相关论文
共 50 条
  • [1] Does nonmetastatic castration-resistant prostate cancer still exist?
    Higano, Celestia S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (06) : 350 - 351
  • [2] Nonmetastatic Castration-Resistant Prostate Cancer
    Hong, Jun Hyuk
    Kim, Isaac Y.
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (03) : 153 - 160
  • [3] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [4] Management of nonmetastatic castration-resistant prostate cancer
    Traboulsi, Samer L.
    Saad, Fred
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 366 - 371
  • [5] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [6] Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
    Yildizhan, Mehmet
    Gemalmaz, Hakan
    Ertek, Mehmet Sirin
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 120 - 127
  • [7] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
  • [8] Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 202 (04): : 660 - 661
  • [9] Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective
    Cancian, Madeline
    Renzulli, Joseph F., II
    UROLOGY, 2018, 116 : 13 - 16
  • [10] Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    Hussain, Maha
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal
    Ferreira, Ubirajara
    Ivashchenko, Petro
    Demirhan, Eren
    Modelska, Katharina
    Phung, De
    Krivoshik, Andrew
    Sternberg, Cora N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2465 - 2474
12345